CRDL (Cardiol Therapeutics) — Quietly Targeting a $250K+ Heart Disease Market With Early Clinical Results That Look Interesting

Been digging into Cardiol Therapeutics ($CRDL) and wanted to share a quick breakdown for discussion—not hype, just the data so far.
They’re developing treatments for inflammatory heart diseases, mainly:
Recurrent pericarditis
Myocarditis
These are conditions where patients often relapse after stopping treatment, and long-term solutions are still limited.

Current standard of care
The only approved therapy right now is Arcalyst, which is extremely expensive:
Roughly $250K–$315K per year per patient, depending on dosing
That creates a massive incentive for a cheaper, effective alternative.

Where $CRDL stands
Phase 1:
Positive safety/early data
No reported side effects
Phase 2 (27 patients):
Pain scores: 5.8 → 2.1 after 8 weeks
CRP inflammation marker: 2.0 mg/dL → ~0.5 mg/dL (near normal range)
Recurrence rate: 5.8 episodes/year → 0.9 episodes/year

Why people are watching it
Clear unmet medical need (limited treatment options)
Extremely high-cost existing therapy
Early data suggests meaningful symptom + inflammation reduction
Moving into larger Phase 3 trial enrollment

Reality check
Still early-stage biotech risk (Phase 3 is where many drugs fail)
Small sample size in Phase 2
Regulatory approval is not guaranteed even with strong data

💬 Open question for discussion:
If Phase 3 data holds up, do you think FDA approval becomes likely here—or is this still a “show me” biotech story?
Not financial advice—just sharing what I found for discussion.